|
|||||
|
|
Randomized,phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma |
|
| Abstract: | |
| Keywords: | inotuzumab ozogamicin B‐cell non‐Hodgkin lymphoma CD22+ antibody‐drug conjugate rituximab |